Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare and evaluate the safety of AVP-923
(dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients.